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ABSTRACT
Introduction: To identify reasons why primary
care physicians (PCPs) do not treat older
patients newly diagnosed with type 2 diabetes
mellitus (T2DM) with antihyperglycemic agents
following diagnosis.
Methods: US PCPs were surveyed via the
internet regarding their reasons for not
treating patients aged [65 years diagnosed
with T2DM and had not yet initiated
antihyperglycemic therapy for C6 months after
diagnosis. PCPs were requested to provide
relevant clinical information for untreated
older patients and select applicable reasons for
not initiating treatment from a list of 35
possibilities, grouped into five categories.
Results: A total of 508 PCPs completed the
online survey and provided complete clinical
data for 770 patients. The reasons provided by
the first-ranked physician for not initiating
antihyperglycemic therapy were related to diet
and exercise (57.5%); mild hyperglycemia
(23.8%); patient’s concerns (13.4%); concerns
about antihyperglycemic agents (3.0%); and
comorbidities and polypharmacy (2.3%). The
‘‘diet and exercise’’ category was the most
common first-ranked non-treatment reason,
regardless of recent hemoglobin A1c (HbA1c)
stratum. Reasons within the ‘‘patient’s
concerns,’’ ‘‘concerns related to
antihyperglycemic agents,’’ and ‘‘comorbidities
and polypharmacy’’ categories tended to be
selected more often as first-ranked reasons by
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form at the 2009 ADA meeting in New Orleans, LA, USA.
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physicians for patients with higher HbA1c
values. Of the 158 patients whose physicians
planned to initiate antihyperglycemic therapy
within the next month, 54.4% already had a most
recent HbA1c value above their physician-stated
threshold for treatment initiation.
Conclusion: In the PCPs studied, there was
a tendency to select appropriate reasons for
non-treatment with antihyperglycemic agents
given their patients’ glycemic status. However,
there was inertia related to the initiation of
pharmacological therapy in some older patients
with newly diagnosed T2DM. Important factors
included physicians’ perceptions of ‘‘mild’’
hyperglycemia and the HbA1c threshold for
using antihyperglycemic agents.
Keywords: Antihyperglycemic agents; Clinical
inertia; Elderly; Non-treatment; Type 2 diabetes
mellitus
INTRODUCTION
The number of people aged C65 years is
increasing, and currently represents
approximately 13.0% of the US population. At
the same time, the incidence and prevalence of
diagnosed type 2 diabetes mellitus (T2DM)
among adults aged C65 years have increased to
values of 2.7% annually and 24.8%, respectively
[1]. Persons aged C65 years diagnosed with
T2DM in the US have morbidity and mortality
rates far in excess of their counterparts
without diabetes, including microvascular
complications and cardiovascular disease [2].
In the UK Prospective Diabetes Studies,
treatment with antihyperglycemic therapies
reduced the risk of microvascular and,
in the metformin arm, macrovascular
disease endpoints among patients with
newly diagnosed T2DM [3, 4]. Importantly,
this early treatment led to sustained benefits
related to the development and progression of
microvascular disease as well as to emergent
risk reduction in macrovascular disease and
all-cause mortality [5]. The American
Diabetes Association (ADA) and the European
Association for the Study of Diabetes
recommend initiating treatment with
metformin, in combination with lifestyle
changes, immediately after the diabetes
diagnosis, with a target hemoglobin A1c
(HbA1c) value of \7.0% for adults [6]. The
American Geriatrics Society also recommends
a target HbA1c of B7.0% for relatively healthy,
older adults [7]. However, specific glycemic
targets may need to be re-evaluated for higher-
risk patients with T2DM in light of the
increased mortality observed in patients
aggressively treated with antihyperglycemic
agents to achieve intensive glucose lowering
glycemic targets [8].
However, many patients aged C65 years are
not prescribed antihyperglycemic agents after
diagnosis of T2DM. In a US employer-based
health insurance data set, 44.0% of individuals
aged C65 years received no antihyperglycemic
therapy in the 12-month period following
T2DM diagnosis [9]. Similarly, in a
retrospective US cohort study, older patients
(age C65 years) with newly diagnosed T2DM
were less likely to have oral antihyperglycemic
therapy initiated following diagnosis than
younger patients [10]. Among patients who
showed disease progression in a 1-year follow-
up period (defined as a HbA1c increase from
\7.0 to C7.0%), the likelihood of initiating
antihyperglycemic therapy decreased by 40.0%
with every decade increase in age [11].
Although there have been studies of physicians’
attitudes toward recommending lifestyle changes
after a diagnosis of T2DM [12, 13], or their
attitudes toward treatment intensification with
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insulin [14–17], there are limited data
evaluating the reasons given by primary care
physicians for not initiating antihyperglycemic
therapy in older patients with T2DM. Therefore,
the objectives of the present study were, first,
to describe the clinical characteristics of
patients aged C65 years who had not been
treated with oral antihyperglycemic therapy in
the 6 or more months following diagnosis of
T2DM, and second, to report the reasons given
by primary care physicians for not initiating




This study was an internet-based survey of a
panel of US primary care physicians, conducted
in November to December 2008. The study was
reviewed and approved by a central institutional
review board (IntegReview, Austin, TX, USA).
The physician panel (TNS Jstreet’s online panel)
used for this study was maintained by TNS
Healthcare at the time of the study and
included approximately 25,000 physicians in
the US covering 37 specialties, including
primary care (n = 5,600 primary care
physicians). The geographical distribution of
primary care physicians in this panel shows
more physicians from the South (32.0%) and
Northeast (26.0%) relative to the Midwest
and West (21.0% each). Primary care physicians
in general practice, family practice, and internal
medicine who regularly participated in
panel-related survey studies were identified and
randomly sent an invitation to participate in the
present survey study (n = 3,401 invitees). If an
invited physician provided satisfactory responses
to a screening questionnaire, the physician was
allowed to enter the survey site and to complete
the patient-related survey. The survey site was
closed shortly after 500 physicians completed the
survey and provided the required information for
their patients. Physicians were compensated for a
completed survey.
Each participating physician was requested
to provide data for one or two older patients
with T2DM, selected randomly on the basis of
an assigned patient’s last name initial to limit
selection bias. Patients, provided by the
physician, had to meet the following inclusion
criteria: age C65 years at the time of T2DM
diagnosis, no antihyperglycemic treatment up
to the time of the survey and for at least
6 months after diagnosis, and at least one
office visit for management of their diabetes
within the previous 6 months. The following
data were collected from patients’ charts and
entered by the physician into online forms:
patient demographics, comorbidities and
associated medication use, and laboratory
measurements (values closest to diagnosis and
the most recent values [i.e., closest to the time
of the survey]). Laboratory measurements at the
time closest to diagnosis included HbA1c
and fasting blood glucose (FBG). The most
recent laboratory measurements included
HbA1c, FBG, blood pressure, lipids, and serum
creatinine.
Patients with a body mass index [25 kg/m2
were included in the classification of
overweight/obese. The estimated glomerular
filtration rate (eGFR) was calculated from the
abbreviated Modification of Diet in Renal
Disease study equation [18]. Microvascular
complications were defined as any history of
neuropathy, retinopathy, or renal disease.
Cardiovascular conditions included any
history of congestive heart failure, ischemic
heart disease, myocardial infarction, peripheral
vascular disease, or stroke.
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Survey
The online survey was developed based on
extensive interviews with an expert panel of
community and academic physicians.
Interviews included discussions regarding the
treatment of older patients, scenarios where
patients are not treated with antihyperglycemic
agents for at least 6 months after an initial
diabetes diagnosis, and potential reasons
relevant to not initiating antihyperglycemic
treatment. After the survey was drafted
according to the experts’ opinions, it was
presented back to the panel for review and
approval. A list of 35 possible reasons for non-
treatment was subsequently provided to the
study physicians. Physicians selected the
reasons why their patients had not been
treated with antihyperglycemic agents in the
6 months or more after diagnosis and also
ranked the selected reasons in order of
importance. A physician could check all the
applicable reasons. Physicians were also asked if
they intended to initiate antihyperglycemic
therapy in the next month for their patient
and, if yes, they were asked to further specify
what threshold HbA1c level would trigger a
decision to start drug therapy.
Data Analysis
Descriptive statistics were used to summarize
patient demographics, disease characteristics,
and reasons for non-treatment with
antihyperglycemic agents. For purposes of
analysis, the 35 reasons for non-treatment were
grouped into five high-level categories: ‘‘diet and
exercise’’ (one item); ‘‘mild hyperglycemia’’
(three items); ‘‘patient’s concerns’’ (nine items);
‘‘concerns related to antihyperglycemic agents’’
(17 items); and ‘‘comorbidities and
polypharmacy’’ (five items). Reasons for
non-treatment were expressed as frequency of
selection for each reason (all reasons analyses)
and for the first-ranked reason (first-ranked
reasons analyses). Descriptive analyses
included the distribution of first-ranked
reasons for non-treatment, by most recent
HbA1c stratum (\7.0, 7.0–7.4, C7.5%), and the
distribution of all reasons for non-treatment by
selected patient characteristics. A small number
of patients had a most recent HbA1c value C7.5%
and, thus, were considered one group in the
stratified analysis.
RESULTS
Physicians Who Completed the Survey
Of the 3,401 primary care physicians invited to
participate, 1,093 accessed the online link until
the survey was closed after reaching the target
number of physicians. Of the 1,093 physicians,
414 were screened out for the following reasons:
258 had less than two older patients with T2DM
currently being treated with diet and exercise
only; 40 had the incorrect specialty; 35 had less
than 3 years of clinical practice; 34 had an
insufficient number of patients meeting all
inclusion criteria; and 47 for various other
reasons. Of those who satisfied the criteria in
the screening questions (n = 679), 508 fully
completed the survey and provided the
required information for their patients. These
508 physicians (77.0% men) had a mean age of
47 years and a mean number of years in clinical
practice of 16 years since post-graduate medical
training.
Patient Characteristics
Complete information was provided by
participating physicians for 770 older patients
with T2DM not treated with antihyperglycemic
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therapy for at least 6 months following
diagnosis (Table 1). These patients had a mean
(±SD) age of 72 (6) years, a mean (±SD) HbA1c
at diagnosis of 7.2% (0.8), and a mean (±SD)
duration of diabetes (i.e., time from diagnosis to
survey date) of 20.9 (23.7) months. In the
cohort of patients (n = 738) with a most recent
HbA1c measurement, the mean (±SD) HbA1c
was 6.7% (0.6; Table 1). Of these patients,
67.0% had a most recent HbA1c value \7.0%,
21.0% had an HbA1c of 7.0–7.4%, and 12.0%
had an HbA1c C7.5% (including 31 patients
with an HbA1c C8.0%).
In a subset of patients with HbA1c
measurements at both ‘‘closest to diagnosis’’
and ‘‘most recent’’ time points (n = 656, or
85.0% of the sample), 15.0% (n = 100)
experienced an increase in HbA1c, with a mean
(±SD) HbA1c increase of 0.37% (0.29).
Physicians’ Reasons for Non-Treatment
with Antihyperglycemic Agent
The frequency of selection of each physician’s
reason for non-treatment is shown in Table 2.
When evaluated by category of reasons, the
‘‘diet and exercise’’ category was selected most
(92.5%) followed by ‘‘mild hyperglycemia’’
(83.6%), ‘‘patient’s concerns’’ (61.3%),
‘‘concerns related to antihyperglycemic agents’’
(49.1%), and ‘‘comorbidities and
polypharmacy’’ (36.9%). Within these five
categories, the most commonly cited reasons
by physicians were: ‘‘try diet and exercise first
before starting drug treatment’’ (92.5%); ‘‘HbA1c
value close to ADA recommended threshold’’
(69.6%); ‘‘patient does not want to take
(additional) medication’’ (51.6%); ‘‘may cause
hypoglycemia’’ (29.5%); and ‘‘patient is taking
several other medications already’’ (25.3%). The
cumulative frequency of first-ranked reasons for
non-treatment in the five categories was 57.5%
of patients (diet and exercise), 23.8% (mild
hyperglycemia), 13.4% (patient’s concerns),
3.0% (concerns related to antihyperglycemic
Table 1 Characteristics of 770 patients provided by the
physicians
Characteristics Mean – SD or
proportion
Males (%) 54
Age (years) 72 ± 6
Age at diabetes diagnosis (years) 71 ± 5
Duration of diabetes (months) 20.9 ± 23.7
BMI (kg/m2) 29.7 ± 4.9
Overweight/obese (%) 74
Laboratory values
HbA1c closest to diabetes diagnosis (%) 7.2 ± 0.8
Most recent HbA1c
a (%) 6.7 ± 0.6
Most recent HbA1c
a\7.0% (%) 67
FBG closest to diagnosis (mg/dL) 155 ± 38
Most recent FBG (mg/dL) 124 ± 23
Most recent FBG C126 mg/dL (%) 43





Microvascular complications (%) 12.7
Neuropathy (%) 3.4
Retinopathy (%) 0.8
Renal disease (%) 10.3
Cardiovascular conditions (%) 17.3
Congestive heart failure (%) 9.0
Ischemic heart disease (%) 8.1
Myocardial infarction (%) 4.7
Peripheral vascular disease (%) 3.9
Stroke (%) 2.6
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agents), and 2.3% (comorbidities and
polypharmacy; Table 2).
Physicians’ First-Ranked Reasons
by Categories for Non-Treatment by HbA1c
Stratum
The ‘‘diet and exercise’’ category was the
first-ranked reason for non-treatment in all
HbA1c strata, with a decrease in selection with
increasing HbA1c levels (Fig. 1). In addition,
while ‘‘mild hyperglycemia’’ was cited as the
first-ranked reason category for non-treatment
by physicians for 27.0% of patients with a most
recent HbA1c \7.0%, it was also the first-ranked
reason for 19.0% with an HbA1c of 7.0–7.4%,
and 13.0% with an HbA1c C7.5% (Fig. 1). In
contrast, ‘‘patient’s concerns’’, ‘‘concerns related
to antihyperglycemic agents’’, or ‘‘comorbidities
and polypharmacy’’ tended to be selected as the
first-ranked reason category for non-treatment
by physicians for more patients with higher
HbA1c values (Fig. 1).
Reasons Selected for Non-Treatment
by Patient Characteristics or Comorbid
Conditions
Physicians appeared to select reasons (using all
reasons analysis) within ‘‘concerns related to
antihyperglycemic agents’’ or ‘‘comorbidities
and polypharmacy’’ categories more often for
patients with pre-existing microvascular
complications, cardiovascular conditions, renal
impairment (i.e., eGFR \60 mL/min/1.72 m2),
or already taking more than three medications.
Duration of diabetes above the median (i.e.,
[12 months) did not appear to impact selected
reasons (Fig. 2).
Physician-Stated Threshold for Initiating
Antihyperglycemic Treatment
Physicians designated 158 patients to begin
treatment with antihyperglycemic agents
within the next month. When physicians were
asked for the HbA1c threshold to initiate
treatment among these patients, the mean
(±SD) HbA1c was 7.1% (0.6). Of these patients,
86 (54.4%) already had a most recent HbA1c
value above their physician-stated threshold for
treatment initiation (median difference
between the most recent HbA1c value and the
threshold value equals 0.5% [min, max: 0.1,
2.8]).
DISCUSSION
This survey of over 500 US primary care
physicians examined their reasons for not
initiating antihyperglycemic treatment in
older patients who had not been treated for at
least 6 months following diagnosis of T2DM.
The characteristics of the present cohort of
patients were generally similar to those of a
Table 1 continued









Total number of medications,
median (range)
3.0 (0–20)
BMI body mass index, HbA1c hemoglobin A1c, eGFR
estimated glomerular ﬁltration rate, FBG fasting blood
glucose
a When the most recent HbA1c was missing, the value
closest to diagnosis was imputed (n = 738)
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Table 2 All and ﬁrst-ranked reasons for non-treatment with antihyperglycemic agents
Reasons All (n5 770) First-ranked (n5 756)
n % n %
Diet and exercise 712 92.5 435 57.5
Try diet and exercise ﬁrst before starting drug treatment 712 92.5 435 57.5
Mild hyperglycemia 644 83.6 180 23.8
HbA1c value stable, drug therapy not necessary 478 62.1 65 8.6
HbA1c value close to ADA recommended threshold 536 69.6 81 10.7
Blood glucose values under control with diet and exercise 507 65.8 34 4.5
Patient’s concerns 472 61.3 101 13.4
Patient’s follow-up visit is overdue 59 7.7 5 0.7
Patient does not want to take (additional) medication 397 51.6 86 11.4
Fear of hypoglycemia 149 19.4 0 0
Fear of weight gain 135 17.5 0 0
Fear of other treatment side effects 162 21.0 2 0.3
Fear to change from diet/exercise to oral agents 119 15.5 0 0
Fear to change from diet/exercise to insulin 100 13.0 0 0
Financial burden (health insurance coverage/patient co-pay) 134 17.4 7 0.9
Drug therapy decreases quality of life 64 8.3 1 0.1
Concerns related to antihyperglycemic agents 378 49.1 23 3.0
May cause hypoglycemia 227 29.5 7 0.9
May cause ﬂuid retention 147 19.1 2 0.3
May cause weight gain 179 23.2 1 0.1
May cause GI side-effects 175 22.7 0 0
May increase risk of fracture 70 9.1 0 0
May increase cardiovascular risk 93 12.1 1 0.1
May increase risk of lactic acidosis 118 15.3 0 0
Uncertainty how to dose certain drug for older patients 46 6.0 1 0.1
Not clear if several agents are safe for older patients 59 7.7 0 0
Efﬁcacy of agents not clear for older patients 48 6.2 0 0
Safety of agents not clear for older patients 67 8.7 0 0
Cognitive burden of therapy administration too high for older patient 67 8.7 4 0.5
Cognitive burden of monitoring blood glucose too high for older patient 67 8.7 1 0.1
Difﬁculties/ability to change patient’s lifestyle 93 12.1 2 0.3
Risk of noncompliance (not related to side-effects) 101 13.1 4 0.5
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US cohort of older patients with newly
diagnosed T2DM [10]. The survey found that
the reasons cited by physicians were
overwhelmingly related to a preference for diet
and exercise or a perception that the patient
had mild hyperglycemia and was in good
glycemic control. The specific reason ‘‘try diet
and exercise first’’ was selected by 92.5% of
physicians. Moreover, 57.5% of physicians
ranked this reason first. The second-most cited
reasons included those in the ‘‘mild
hyperglycemia’’ category, with physicians
selecting any one of the items in this category
83.6% of the time (ranked first by 23.8% of
physicians). Collectively, these two categories
accounted for over 80.0% of first-ranked reasons
for not initiating treatment. Using a similar
survey in the UK, 79.0% of general practitioners
Fig. 1 First-ranked physician’s reasons for non-treatment
with antihyperglycemic agents (AHAs), stratiﬁed by most
recent HbA1c level before the survey. HbA1c hemoglobin
A1c
Fig. 2 Reasons provided by physicians for non-treatment
with antihyperglycemic agents (AHAs) by select patient
characteristics and comorbidities (all reasons analysis).
eGFR estimated glomerular ﬁltration rate
Table 2 continued
Reasons All (n5 770) First-ranked (n5 756)
n % n %
Risk of noncompliance due to side-effects 95 12.3 0 0
Lack of monitoring due to physical limitations (e.g., dexterity) 55 7.1 0 0
Comorbidities and polypharmacy 284 36.9 17 2.3
Patient has other severe disease(s) 118 15.3 7 0.9
Medical diabetes treatment is contraindicated 22 2.9 1 0.1
Patient is taking several other medications already 195 25.3 8 1.1
Risk of side effects 184 23.9 1 0.1
Risk of drug–drug interactions 110 14.3 0 0
ADA American Diabetes Association, GI gastrointestinal, HbA1c hemoglobin A1c
Page 8 of 12 Diabetes Ther (2012) 3:5
123
selected their first-ranked reason for not
initiating antihyperglycemic therapy from the
‘‘mild hyperglycemia’’ category (the ‘‘diet and
exercise’’ category was not a standalone
category in this survey) for their older and
younger patients with newly diagnosed T2DM
[19].
The proportion of physicians selecting
reasons related to ‘‘diet and exercise,’’ or ‘‘mild
hyperglycemia’’ as reasons for non-treatment
with antihyperglycemic agents tended to
decline as the patients’ HbA1c values increased.
Although these reasons may have been
appropriate for patients with a most recent
HbA1c value \7.0%, selection of these reasons
continued for many untreated patients whose
most recent HbA1c value was C7.0%.
Furthermore, when physicians were asked if
they planned to initiate antihyperglycemic
therapy within the next month for their
patients, the mean HbA1c threshold for
initiating therapy indicated by the physicians
was approximately 7.0%. However, more than
half the patients identified by the physicians for
future pharmacologic treatment already had an
HbA1c level above this threshold. These results
demonstrate discordance between physicians’
theoretical and actual clinical actions for their
older patients with T2DM.
For patients whose most recent HbA1c level
was C7.0%, physicians tended to select
patient-centric reasons for not initiating
glycemic therapy in the present study. The
most-selected reasons within the ‘‘patient’s
concerns’’ category were related to taking
additional medications, fear of side effects,
including hypoglycemia and weight gain,
and increased financial burden. In the
aforementioned UK survey by Zhang et al.
[19], general practitioners were more likely to
select reasons related to side effects, disease or
medication burden for patients, and well-being
of the patient for their older patients compared
to younger ones. Interestingly, ‘‘not wanting to
take additional medication’’ was behind only
‘‘try diet and exercise’’ as a first-ranked
reason for not initiating therapy in the present
study. Although patient fear or physician
concern of the common side effects with
antihyperglycemic agents (e.g., hypoglycemia,
weight gain, gastrointestinal intolerance, and
fluid retention) was selected as reasons by
approximately 17.0–30.0% of physicians, none
of these reasons were selected by more than
1.0% of physicians as a first-ranked reason.
This is in agreement with the findings of
Grant et al. [20], who reported that a patient’s
tendency to complain about side effects was
not a major consideration when initiating
antihyperglycemic therapy.
Consistent with the main reasons for not
initiating an antihyperglycemic agent (diet and
exercise, and mild hyperglycemia) observed in
this study, physicians generally report that
lifestyle change was a key component of
diabetes treatment. However, physicians have
also indicated that it was difficult for patients to
change their lifestyle or diet [12, 13].
In response to a questionnaire given to
healthcare providers in Finland regarding a
lifestyle change, almost all (98.0%) physicians
reported that lifestyle change was always or
nearly always a central part of treatment [13].
Most (83.0%) reported that the biggest barrier to
treatment of diabetes was always or nearly
always the patients’ unwillingness to change
their lifestyle [13]. Likewise, most (87.0%)
doctors in Denmark, responding to a
questionnaire regarding a change in patient
diet, thought that changing their diabetic
patients’ food habits was difficult or very
difficult [12]. Furthermore, the proportion of
T2DM patients treated with diet alone was
positively associated with the level of their
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doctors’ dietary counseling skills, suggesting
physicians who were less skilled in providing
dietary advice prescribed antihyperglycemic
agents [12]. Information on recommended
lifestyle changes and dietary advice was not
collected from the physicians in the present
study.
There is a paucity of evidence regarding the
factors that influence the initiation of oral
antihyperglycemic agents in clinical practice.
Pani et al. [11] found that, despite disease
progression in untreated patients with T2DM,
the likelihood of initiating therapy was lower as
the patient’s age increased. In an observational
study of US patients with newly diagnosed
T2DM, age C65 years was a significant factor
for not initiating oral antihyperglycemic
therapy after adjusting for baseline and time-
varying covariates [10]. In newly diagnosed
T2DM patients C40 years of age, general
practitioners tended to set the goal of
normoglycemia for patients who were younger
and in better overall health at diagnosis [21].
Conversely, age does not always appear to be a
major factor for initiating therapy in untreated
patients with T2DM. In 603 newly diagnosed
T2DM patients from a Dutch town, the time to
first treatment with an oral antihyperglycemic
agent was shortest in patients with the highest
fasting plasma glucose values at the time of
diagnosis, whereas age, body weight, and
history of cardiovascular disease did not
influence the initiation of therapy [22]. Grant
et al. [20] surveyed US physicians (specialists
and generalists) to determine the factors they
considered when deciding the initial
antihyperglycemic therapy to prescribe to
untreated patients with T2DM. The most
common factors were the patient’s overall
health status and comorbidities (89.0% of
all respondents), HbA1c value (74.0%), and
patient’s weight (66.0%). Patient’s age tended
to be considered more by specialists (38.0%)
compared with generalists (22.0%) [20]. In the
present study, physicians selected reasons
within the ‘‘concerns related to
antihyperglycemic agents’’ or ‘‘comorbidities
and polypharmacy’’ categories more often for
non-treatment in patients with pre-existing
microvascular complications, cardiovascular
conditions, renal impairment, or already
taking numerous medications. Collectively,
the research suggests that patient’s disease and
comorbidity status, glycemic control at
diagnosis, and younger age influence the
initiation of antihyperglycemic therapy.
This study has several limitations. The survey
was developed and approved by experts, but no
external validation was performed. To limit
selection bias, physicians were instructed to
select a patient on the basis of a randomly
assigned last name initial and to provide
information on the first patient with this
initial who met entry criteria. However,
because of the online nature of the survey, it
could not be verified whether the physicians
adhered to this specific protocol for patient
selection. All reported laboratory measures
closest to diagnosis were included in the
analysis, regardless of the timing of the
measurement. The question regarding the
physician’s intent to treat a patient within the
next month may have produced responses
biased in favor of treatment. The results
pertain to a sample of US primary care
physicians and may not be generalizable to all
primary care physicians or to endocrinologists
and other diabetes specialists. Although nearly
one-third of invited physicians accessed the
survey invitation link, the final response rate
could affect the generalizability of the results.
Lastly, participating physicians may have been
more confident in their management of T2DM
in older patients than nonparticipating
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physicians. Thus, the present findings may
underestimate the issue of non-treatment in
the general population.
In conclusion, in this survey study of
physicians, two-thirds of patients had
appropriate glycemic control (i.e., HbA1c
\7.0%) and selection of reasons for non-
treatment with antihyperglycemic agents
related to this appears to be an appropriate
clinical decision for many of these patients. The
data from the present study also indicate that, in
the group of physicians surveyed, there is
substantial inertia related to the initiation of
pharmacological therapy in older patients with
newly diagnosed T2DM. Physician-reported
reasons for non-treatment suggest that there are
substantial barriers to drug use in clinical
practice, including physicians’ perceptions of
‘‘mild’’ hyperglycemia and the HbA1c threshold
for the use of antihyperglycemic agents. One-
third of the patients had an HbA1c above goal
(with HbA1c 7.0–7.4% in 21.0% of patients and
HbA1c C7.5% in 12.0%), and many of these
patients already had cardiovascular or
microvascular complications and risk factors.
The timing of initiation of drug therapy for
T2DM in the older population is an issue
requiring further clarification. The present
study suggests the need for more explicit
guidelines for physicians who treat such patients.
ACKNOWLEDGMENTS
E.M., Q.Z., C.K., L.R., and M.N.F. were involved
in the concept and design of the study. E.M.,
Q.Z., and C.K. were involved in the data
collection and/or analysis. All authors were
involved in interpretation of the results.
M.J.D. and E.M. drafted the article and all
authors were involved in the critical revision
and approval of the article. E.M. is the guarantor
for this article, and takes responsibility for the
integrity of the work as a whole. Medical
writing assistance was provided by Julia
Vishnevetsky and Melissa Stauffer, PhD
(SCRIBCO, Newtown, PA, USA) on an early
draft of this manuscript with funding provided
by Merck Sharp & Dohme Corp., a subsidiary of
Merck & Co., Inc., Whitehouse Station, NJ,
USA.
Conflict of interest. This study was funded
by Merck Sharp & Dohme Corp., a subsidiary of
Merck & Co., Inc., Whitehouse Station, NJ,
USA. E.M., Q.Z., M.J.D., and L.R. are employees
of Merck Sharp & Dohme Corp., Whitehouse
Station, NJ, USA. C.K. and M.N.F. have no
disclosures related to this study.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution Noncommercial License which
permits any noncommercial use, distribution,
and reproduction in any medium, provided the
original author(s) and source are credited.
REFERENCES
1. Sloan FA, Bethel MA, Ruiz D Jr, Shea AM, Feinglos
MN. The growing burden of diabetes mellitus in the
US elderly population. Arch Intern Med.
2008;168:192–9.
2. Bethel MA, Sloan FA, Belsky D, Feinglos MN.
Longitudinal incidence and prevalence of adverse
outcomes of diabetes mellitus in elderly patients.
Arch Intern Med. 2007;167:921–7.
3. UK Prospective Diabetes Study (UKPDS) Group.
Intensive blood-glucose control with
sulphonylureas or insulin compared with
conventional treatment and risk of complications
in patients with type 2 diabetes (UKPDS 33). Lancet.
198;352:837–53.
4. UK Prospective Diabetes Study (UKPDS) Group.
Effect of intensive blood-glucose control with
metformin on complications in overweight
Diabetes Ther (2012) 3:5 Page 11 of 12
123
patients with type 2 diabetes (UKPDS 34). Lancet.
1998;352:854–65.
5. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil
HA. 10-year follow-up of intensive glucose control
in type 2 diabetes. N Engl J Med. 2008;359:1577–89.
6. American Diabetes Association. Standards of
medical care in diabetes—2012. Diabetes Care.
2012;35(Suppl. 1):S11–63.
7. Brown AF, Mangione CM, Saliba D, Sarkisian CA.
Guidelines for improving the care of the older
person with diabetes mellitus. J Am Geriatr Soc.
2003;51:S265–80.
8. Action to Control Cardiovascular Risk in Diabetes
Study Group; Gerstein HC, Miller ME, Byington RP,
et al. Effects of intensive glucose lowering in type 2
diabetes. N Engl J Med. 2008;358:2545–59.
9. Erwin G, Iyer S, Rajagopalan R, et al. Type 2 diabetes
mellitus treatment patterns and healthcare costs in
the elderly population. Dis Manag Health
Outcomes. 2006;14:75–83.
10. Zhang Q, Rajagopalan S, Marrett E, Davies MJ,
Radican L, Engel SS. Time to treatment initiation
with oral antihyperglycaemic therapy in US
patients with newly diagnosed type 2 diabetes.
Diabetes Obes Metab. 2012;14:149–54.
11. Pani LN, Nathan DM, Grant RW. Clinical predictors
of disease progression and medication initiation in
untreated patients with type 2 diabetes and A1C
less than 7%. Diabetes Care. 2008;31:386–90.
12. de Fine Olivarius N, Palmvig B, Andreasen AH,
Thorgersen JT, Hundrup C. An educational model
for improving diet counselling in primary care: a
case study of the creative use of doctors’ own diet,
their attitudes to it and to nutritional counselling
of their patients with diabetes. Patient Educ Couns.
2005;58:199–202.
13. Jallinoja P, Absetz P, Kuronen R, et al. The dilemma
of patient responsibility for lifestyle change:
perceptions among primary care physicians and
nurses. Scand J Prim Health Care. 2007;25:244–9.
14. Agarwal G, Nair K, Cosby J, et al. GPs’ approach to
insulin prescribing in older patients: a qualitative
study. Br J Gen Pract. 2008;58:569–75.
15. Hayes RP, Fitzgerald JT, Jacober SJ. Primary care
physician beliefs about insulin initiation in patients
with type 2 diabetes. Int J Clin Pract.
2008;62:860–8.
16. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to
insulin therapy among patients and providers:
results of the cross-national Diabetes Attitudes,
Wishes, and Needs (DAWN) study. Diabetes Care.
2005;28:2673–9.
17. van Avendonk MJ, Gorter KJ, van den DM, Rutten
GE. Insulin therapy in type 2 diabetes is no longer a
secondary care activity in the Netherlands. Prim
Care Diabetes. 2009;3:23–8.
18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N,
Roth D. A more accurate method to estimate
glomerular filtration rate from serum creatinine: a
new prediction equation. Modification of Diet in
Renal Disease Study Group. Ann Intern Med.
1999;130:461–70.
19. Zhang Q, Marrett E, Jameson K, et al. Reasons given
by general practitioners for non-treatment
decisions in younger and older patients with
newly diagnosed type 2 diabetes mellitus in the
United Kingdom: a survey study. BMC Endocr
Disord. 2011;11:17.
20. Grant RW, Wexler DJ, Watson AJ, et al. How
doctors choose medications to treat type 2
diabetes: a national survey of specialists and
academic generalists. Diabetes Care.
2007;30:1448–53.
21. Hansen LJ, Olivarius NF, Siersma V, Drivsholm T,
Andersen JS. Individualised treatment goals in
diabetes care. Scand J Prim Health Care.
2004;22:71–7.
22. Spoelstra JA, Stolk RP, Klungel OH, et al. Initiation
of glucose-lowering therapy in type 2 diabetes
mellitus patients in general practice. Diabet Med.
2004;21:896–900.
Page 12 of 12 Diabetes Ther (2012) 3:5
123
